---
title: "Predicting AML Progression with Peripheral Blood, FLT3 Measures, and Medication Adherence"
id: "medrxiv-8-a-multivariable-mixed-effects-framework-for-predicting-disease-progression-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-a-multivariable-mixed-effects-framework-for-predicting-disease-progression-in"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1?rss=1"
published_at: "2026-10-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Predicting AML Progression with Peripheral Blood, FLT3 Measures, and Medication Adherence
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-a-multivariable-mixed-effects-framework-for-predicting-disease-progression-in
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1?rss=1)
- **Published At:** 2026-10-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This longitudinal cohort preprint evaluated 66 acute myeloid leukemia (AML) patients across 272 serial clinical encounters to identify low-burden predictors of clinical deterioration. - The study combined routine peripheral hematology (WBC, hemoglobin), targeted molecular transcripts (FLT3, NPM1, DNMT3A), soluble FLT3 protein quantification, and measured medication adherence as candidate predictors. - Data were collected at discrete follow-up intervals (days 0, 14, 41, 71, 78) and analyzed using generalized linear mixed-effects models (GLMM) with patient-specific random intercepts to account for repeated measures. - Leukocyte expansion strongly inversely correlated with hemoglobin (r = -0.877, p < 0.001), interpreted as marrow infiltration and erythroid suppression in progressive disease. - In multivariable mixed-effects analyses, higher **WBC** (adjusted odds ratio [aOR] 1.52 per 1-SD increase; 95% CI 1.24–1.86; p < 0.001) and lower medication adherence (aOR 0.58; 95% CI 0.44–0.76; p < 0.001) were independent predictors of progression to critical deterioration or disease-related death. - Integrating targeted molecular markers (including **FLT3** transcript and soluble protein levels) with hematologic indices and adherence improved model calibration and discrimination relative to single-domain models (ΔAIC ≥ 116; Harrell’s C-index = 0.81). - The authors propose that combining accessible peripheral indices, targeted molecular quantification, and adherence metrics offers a scalable risk-stratification approach for hematologic malignancies. - The report is a preprint and not peer reviewed; IRB approval and participant consent were reported; data are available on reasonable request from the corresponding author.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=bJDB8iS4bYKNWivWwDuIjNdweDSXcNW11ISU79rBZ2M-1791316768.7946455-1.2.1.1-0C99ol_2NQu24IZVsdhiJfJBozZhWITiWuMEqK_lfFdGpvisJIG0CSMjRvT0uSq2) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # A Multivariable Mixed-Effects Framework for Predicting Disease Progression in Acute Myeloid Leukemia Using Peripheral Hematology, FLT3 Expression, and Patient Compliance Mohammad Mahdi Amiri Dumar, Mitra Aghajani doi: https://doi.org/10.64898/2026.10.04.26364699 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Mohammad Mahdi Amiri Dumar 1 Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mohammad%2BMahdi%2BAmiri%2BDumar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Amiri%20Dumar%20MM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMohammad%2BMahdi%2BAmiri%2BDumar%2B) Mitra Aghajani 2 University of Alborz, Department of Paramedical Sciences, Karaj, Iran * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mitra%2BAghajani%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aghajani%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMitra%2BAghajani%2B) * For correspondence: sahebsima@outlook.com * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1314788/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1314788/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1314788/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1314788/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1314788/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: The clinical course of acute leukemias and related hematologic neoplasms is defined by aggressive clonal proliferation, severe hematopoietic disruption, and recurrent molecular alterations. Although serial bone marrow biopsies, multiparameter flow cytometry, and next-generation sequencing remain standard surveillance modalities, procedural invasiveness, high costs, and operational turnaround times limit their frequency. Minimally invasive, scalable biomarkers integrating routine hematologic indices, targeted gene expression, circulating oncoprotein levels, and patient compliance metrics may provide an accessible framework for dynamic monitoring. Methods: In this longitudinal cohort study of 66 patients across 272 serial encounters (discrete follow-up intervals: days 0, 14, 41, 71, and 78), we assessed the prognostic value of peripheral complete blood counts (white blood cell count [WBC], hemoglobin [Hb]), molecular indicators (FLT3, NPM1, and DNMT3A transcript levels; targeted soluble FLT3 quantification), and medication adherence. The primary clinical endpoint was longitudinal progression to critical deterioration or disease-related mortality. Generalized linear mixed-effects models (GLMM) with patient-specific random intercepts were constructed to account for intra-subject repeated measures. Predictors were standardized per 1-SD increment. Model performance was assessed via the Akaike Information Criterion (AIC) and the Concordance index (C-index). Results: Leukocyte expansion correlated inversely with hemoglobin concentration (r=-0.877, p The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.01.26364061v1 "Right Versus Left Ventricular Myofiber Orientation in Various Congenital Heart Diseases Analyzed with X-Ray Phase-Contrast Tomography")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.04.26363713v1 "Acquisition Speed versus Spatial Resolution in Ultra-High-Resolution Photon-Counting CT: Phantom Study to Guide Protocol Development") Posted October 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/06/2026.10.04.26364699.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.04.26364699v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/06/2026.10.04.26364699.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) A Multivariable Mixed-Effects Framework for Predicting Disease Progression in Acute Myeloid Leukemia Using Peripheral Hematology, FLT3 Expression, and Patient Compliance Mohammad Mahdi Amiri Dumar, Mitra Aghajani medRxiv 2026.10.04.26364699; doi: https://doi.org/10.64898/2026.10.04.26364699 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364699v1%26text%3DA%2520Multivariable%2520Mixed-Effects%2520Framework%2520for%2520Predicting%2520Disease%2520Progression%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Using%2520Peripheral%2520Hematology%252C%2520FLT3%2520Expression%252C%2520and%2520Patient%2520Compliance "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364699v1%26t%3DA%2520Multivariable%2520Mixed-Effects%2520Framework%2520for%2520Predicting%2520Disease%2520Progression%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Using%2520Peripheral%2520Hematology%252C%2520FLT3%2520Expression%252C%2520and%2520Patient%2520Compliance "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364699v1%26title%3DA%2520Multivariable%2520Mixed-Effects%2520Framework%2520for%2520Predicting%2520Disease%2520Progression%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Using%2520Peripheral%2520Hematology%252C%2520FLT3%2520Expression%252C%2520and%2520Patient%2520Compliance%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364699v1%26title%3DA%2520Multivariable%2520Mixed-Effects%2520Framework%2520for%2520Predicting%2520Disease%2520Progression%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Using%2520Peripheral%2520Hematology%252C%2520FLT3%2520Expression%252C%2520and%2520Patient%2520Compliance "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.04.26364699) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (626) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (340) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4885) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (486) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (421) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (659) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1644) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16067) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1218) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7129) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (737) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1073) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5125) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1447) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1793) * [Hematology](https://www.medrxiv.org/collection/hematology) (590) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1355) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16360) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1185) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (678) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (729) * [Neurology](https://www.medrxiv.org/collection/neurology) (7388) * [Nursing](https://www.medrxiv.org/collection/nursing) (370) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1102) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1263) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1010) * [Oncology](https://www.medrxiv.org/collection/oncology) (3659) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1066) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (399) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (460) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (483) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (142) * [Pathology](https://www.medrxiv.org/collection/pathology) (711) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1823) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (741) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (777) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5988) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9836) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2465) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1479) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1257) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (651) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (786) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (588) * [Surgery](https://www.medrxiv.org/collection/surgery) (786) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (310) * [Urology](https://www.medrxiv.org/collection/urology) (298) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no community reviews for this paper._ Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Automated Evaluations: _There are no automated evaluations for this paper._ Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Video medRxiv partners with conferences and institutions to display recordings of talks and seminars related to preprints. These are posted with the consent of the authors. Video: _There are no videos for this paper._ Powered by [![Hypothes.is logo](https://connect.biorxiv.org/eval/hypothesis.png)](https://web.hypothes.is/) Powered by [![Altmetric logo](https://connect.biorxiv.org/eval/altmetric.png)](https://www.altmetric.com/) ## Follow this preprint X You ca
## Related Clinical Research

- [TP53-driven clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease](https://medichelpline.com/clinical-feed/medrxiv-13-intense-tp53-pathway-selection-drives-clonal-evolution-from-bone-marrow-failure.md)
- [Whole-genome sequencing identifies rare coding variants and key genes associated with acute myeloi](https://medichelpline.com/clinical-feed/medrxiv-21-prioritizing-genes-and-rare-protein-coding-variants-in-acute-myeloid-leukemia.md)
- [Olive oil before carbs and blood sugar: what the mouse study found](https://medichelpline.com/clinical-feed/medical-news-today-0-olive-oil-shot-trend-what-science-really-says-about-fat-and-glucose-response.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.